Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT07610174
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Sponsor
- Registry
-
NCT07610174
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07610174. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-04-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
- Acronym
- SYNCARDIA-HF
- Condition
- Heart Failure
- Condition
- Heart Valve Prosthesis
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- Dapagliflozin (10mg Tab)
- Lead sponsor
- Kafrelsheikh University
Record details
- Record id
cardio:ct-nct07610174- Content hash
0f3a45b011de7de48ec332f827e1d71dfc814a0b2a916072b54cab65907ec207